Peptide questions · Efinopegdutide
Efinopegdutide side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for efinopegdutide are nausea, vomiting and diarrhea; the library’s evidence on it includes controlled trials in people.
Its safety note opens: efinopegdutide has no label: it is still in trials.
What is commonly reported with efinopegdutide
- Nausea
- Vomiting
- Diarrhea
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |

Model. Individual results vary.
Which efinopegdutide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on efinopegdutide’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is efinopegdutide’s own.
What the efinopegdutide safety notes say
The library’s safety note
Efinopegdutide has no label: it is still in trials. In the 52-week phase 2b MASH trial, the most common side effects were GI, most often at 10 mg; 11% on 10 mg stopped for side effects vs 3% to 4% on 4 and 7 mg and 1% on placebo. In an earlier obesity trial that started at full dose with no step-up, nausea and vomiting were much more common than on placebo, which is why later trials step up from 2 mg. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
The library’s interaction note
No study of efinopegdutide with other medicines has been published. Like other GLP-1 drugs it slows stomach emptying, which can change how oral medicines are absorbed, and it is not stacked with another GLP-1. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the efinopegdutide reports come from
The library rates the evidence on efinopegdutide as moderate: animal studies plus some human data.
Of the library’s 7 research notes on efinopegdutide, 6 rest on randomized trials and 1 on community reports.
Our 3 study pages on efinopegdutide: 3 randomized trials.
So efinopegdutide has controlled trials in people to set its listed effects against.
What our efinopegdutide study pages report on safety
Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo
Randomized trial, human, 2026: Gut side effects were the most common, and they were highest at 10 mg. At 10 mg, 11% stopped treatment due to side effects, versus 3-4% at the lower doses and 1% on placebo.
Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide
Randomized trial, human, 2023: Side effects were slightly more common with efinopegdutide, mostly stomach and gut problems. In a head-to-head trial, efinopegdutide cut liver fat more than semaglutide at these doses, with similar weight loss and somewhat more gut side effects.
Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks
Randomized trial, human, 2021: Side effects, mainly nausea and vomiting, were more common than on placebo, and 144 of 195 people (73.8%) finished treatment. In people with type 2 diabetes and severe obesity, efinopegdutide lowered weight in a dose-linked way over 12 weeks, but it did not improve blood sugar control and caused more nausea and vomiting than placebo.
Questions people ask
What are the side effects of efinopegdutide?
The side effects most commonly reported for efinopegdutide are nausea, vomiting and diarrhea; the library’s evidence on it includes controlled trials in people.
Do efinopegdutide’s side effects come from human studies?
The library rates the evidence on efinopegdutide as moderate, and the library’s evidence on it includes controlled trials in people.
Which efinopegdutide side effects are its own?
None: each effect the library lists for efinopegdutide is listed for at least one other metabolic & GLP-1 compound too.
Does efinopegdutide interact with other medicines?
The library’s interaction note on efinopegdutide begins: No study of efinopegdutide with other medicines has been published.